NCT03154918 is a Phase 2 clinical trial of GLIDE in Lymphoma, Extranodal NK-T-Cell, sponsored by Sichuan University.

Who is sponsoring NCT03154918?

NCT03154918 is sponsored by Sichuan University.

What drugs are being tested in NCT03154918?

Interventions in NCT03154918: GLIDE.

What condition does NCT03154918 study?

NCT03154918 studies Lymphoma, Extranodal NK-T-Cell.

Is NCT03154918 still recruiting?

NCT03154918 is currently status unknown. Last updated 8 November 2017.

Last reviewed 2017-11-08 · How we verify

NCT03154918

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma

Status unknown Phase 2 Last updated 8 November 2017

What this trial tests

Phase 2 trial testing GLIDE in Lymphoma, Extranodal NK-T-Cell in 60 participants. Status unknown.

Timeline

1 June 2017

Primary endpoint
31 December 2020

30 March 2021

Quick facts

Lead sponsor	Sichuan University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 June 2017
Primary completion	31 December 2020
Estimated completion	30 March 2021
Sites	1 location across China

Drugs / interventions tested

GLIDE — full drug profile →

Conditions studied

Lymphoma, Extranodal NK-T-Cell — all drugs for Lymphoma, Extranodal NK-T-Cell →

Sponsor

Sichuan University

Who can join

Adults 18 to 65, any sex, with Lymphoma, Extranodal NK-T-Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to explore the efficacy and safety of GLIDE regiment in patients with aggressive NK/T cell lymphoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of GLIDE

Trials testing the same drug.

NCT03091933 — Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matche · Phase 1, PHASE2 · unknown

Other Sichuan University trials

Trials by the same sponsor.

NCT07501169 — Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lun · Phase 2 · not yet recruiting
NCT07362732 — Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection · EARLY_PHASE1 · not yet recruiting
NCT07374250 — Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332663 — Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection · EARLY_PHASE1 · not yet recruiting
NCT07258147 — Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03154918 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sichuan University
Last refreshed: 8 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03154918.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing